1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. North America Glioma Treatment Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. North America Glioma Treatment Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Increase in Prevalence of High- Grade Glioma
- 5.1.2 Increasing Various Initiatives Undertaken by the Regional and State Governments
5.2 Market Opportunities
- 5.2.1 Increasing Opportunities in Emerging Economies
5.3 Future Trends
- 5.3.1 Increasing Drug Approval for Glioma Treatment
5.4 Impact of Drivers and Restraints
6. North America Glioma Treatment Market Regional Analysis
6.1 North America Glioma Treatment Market Overview
6.2 North America Glioma Treatment Market Revenue 2020-2030 (US$ Million)
6.3 North America Glioma Treatment Market Forecast Analysis
7. North America Glioma Treatment Market Analysis – by Disease
7.1 Astrocytoma
- 7.1.1 Overview
- 7.1.2 Astrocytoma: North America Glioma Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Oligoastrocytoma
- 7.2.1 Overview
- 7.2.2 Oligoastrocytoma: North America Glioma Treatment Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Oligodendroglioma
- 7.3.1 Overview
- 7.3.2 Oligodendroglioma: North America Glioma Treatment Market – Revenue and Forecast to 2031 (US$ Million)
8. North America Glioma Treatment Market Analysis – by Treatment Type
8.1 Surgery
- 8.1.1 Overview
- 8.1.2 Surgery: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.2 Chemotherapy
- 8.2.1 Overview
- 8.2.2 Chemotherapy: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Radiation Therapy
- 8.3.1 Overview
- 8.3.2 Radiation Therapy: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Glioma Treatment Market Analysis – by Grade
9.1 Low Grade
- 9.1.1 Overview
- 9.1.2 Radiation Therapy: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9.2 High Grade
- 9.2.1 Overview
- 9.2.2 Radiation Therapy: North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Glioma Treatment Market – North America Analysis
10.1 North America
- 10.1.1 North America Glioma Treatment Market Breakdown, by Key
Country, 2023 and 2030 (%)
- 10.1.1.1 North America Glioma Treatment Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 US:
North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.1.1 US: North America Glioma Treatment Market Breakdown, by Disease
- 10.1.1.1.2 US: North America Glioma Treatment Market Breakdown, by Treatment Type
- 10.1.1.1.3 US: North America Glioma Treatment Market Breakdown, by Grade
- 10.1.1.2 Canada:
North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.2.1 Canada: North America Glioma Treatment Market Breakdown, by Disease
- 10.1.1.2.2 Canada: North America Glioma Treatment Market Breakdown, by Treatment Type
- 10.1.1.2.3 Canada: North America Glioma Treatment Market Breakdown, by Grade
- 10.1.1.3 Mexico :
North America Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
- 10.1.1.3.1 Mexico : North America Glioma Treatment Market Breakdown, by Disease
- 10.1.1.3.2 Mexico : North America Glioma Treatment Market Breakdown, by Treatment Type
- 10.1.1.3.3 Mexico : North America Glioma Treatment Market Breakdown, by Grade
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. North America Glioma Treatment Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Amgen Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Amneal Pharmaceuticals Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Arbor Pharmaceuticals LLC
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Biocon Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 F. Hoffmann-La Roche Ltd
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Karyopharm Therapeutics Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Merck & Co Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Pfizer Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Sun Pharmaceutical Industries Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Teva Pharmaceutical Industries Ltd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights